Q3 Earnings Forecast for VolitionRx Issued By HC Wainwright

Key Points

• HC Wainwright raised their Q3 2025 earnings per share estimate for VolitionRx from ($0.05) to ($0.01), reflecting a more optimistic outlook for the company's financial performance.
• VolitionRx's stock currently holds an average buy rating with a price target of $3.50, despite recent mixed reviews from various analysts regarding the stock's potential.
• Institutional investors are actively trading in VolitionRx, with significant acquisitions reported in the last quarter, indicating growing interest in the company's future prospects.

VolitionRx Limited (NYSE:VNRX - Free Report) - Equities research analysts at HC Wainwright lifted their Q3 2025 EPS estimates for shares of VolitionRx in a research report issued to clients and investors on Monday, August 18th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.01) for the quarter, up from their prior estimate of ($0.05). The consensus estimate for VolitionRx's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for VolitionRx's FY2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.03) EPS.

A number of other equities research analysts have also recently commented on VNRX. D. Boral Capital reaffirmed a "buy" rating and set a $5.00 price objective on shares of VolitionRx in a research note on Friday, August 15th. Jones Trading raised shares of VolitionRx to a "strong-buy" rating and set a $3.00 price objective on the stock in a research note on Tuesday, June 10th. Finally, Wall Street Zen began coverage on shares of VolitionRx in a research note on Thursday, May 15th. They set a "sell" rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $3.50.

VolitionRx Price Performance

Shares of NYSE VNRX opened at $0.6730 on Wednesday. The stock has a market capitalization of $69.98 million, a price-to-earnings ratio of -1.87 and a beta of 1.26. VolitionRx has a 12 month low of $0.3951 and a 12 month high of $0.94. The firm's 50 day simple moving average is $0.70 and its 200-day simple moving average is $0.59.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in VNRX. Two Sigma Securities LLC acquired a new position in VolitionRx during the fourth quarter valued at approximately $29,000. Northern Trust Corp grew its stake in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after buying an additional 28,579 shares during the last quarter. Lagoda Investment Management L.P. grew its stake in shares of VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after buying an additional 1,481,000 shares during the last quarter. Millennium Management LLC bought a new stake in shares of VolitionRx during the fourth quarter worth $36,000. Finally, Silverberg Bernstein Capital Management LLC grew its stake in shares of VolitionRx by 42.8% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock worth $153,000 after buying an additional 60,209 shares during the last quarter. 8.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other VolitionRx news, Director Guy Archibald Innes purchased 78,125 shares of the company's stock in a transaction dated Tuesday, August 5th. The stock was bought at an average cost of $0.64 per share, for a total transaction of $50,000.00. Following the completion of the transaction, the director owned 966,814 shares in the company, valued at approximately $618,760.96. This represents a 8.79% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Cameron John Reynolds purchased 78,125 shares of the company's stock in a transaction dated Tuesday, August 5th. The stock was acquired at an average price of $0.64 per share, with a total value of $50,000.00. Following the completion of the transaction, the chief executive officer owned 2,609,847 shares of the company's stock, valued at $1,670,302.08. This represents a 3.09% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 188,750 shares of company stock valued at $118,175. Corporate insiders own 10.40% of the company's stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.